How many insider trades does FilingIQ track for FULC?

FilingIQ tracks 140 Form 4 insider transactions for FULC (Fulcrum Therapeutics, Inc.), covering filings from Jul 22, 2019 onwards. 1 of those were filed in the last 90 days.

Are FULC insiders net buyers or net sellers?

Across the full Form 4 history for FULC, 21 transactions (15%) were open-market purchases and 69 (49%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does FULC insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is FULC in?

Fulcrum Therapeutics, Inc. (FULC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $725.67M.

FULC insider trading

NasdaqGM Healthcare

Fulcrum Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

140

Last 90 days

Buys / sells

15% / 49%

Market cap

$725.67M

About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial. It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Company website: www.fulcrumtx.com

FULC insider activity at a glance

FilingIQ has scored 140 insider transactions for FULC since Jul 22, 2019. The most recent filing in our index is dated Apr 23, 2026.

Across the full history, 21 open-market purchases and 69 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on FULC insider trades is 52.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live FULC trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding FULC

COWEN AND COMPANY, LLC

$23.45M · 1.5% of AUM

STEMPOINT CAPITAL LP

$4.32M · 1.3% of AUM

Exome Asset Management LLC

$3.06M · 2.3% of AUM

Frequently asked

How many insider trades does FilingIQ track for FULC?: FilingIQ tracks 140 Form 4 insider transactions for FULC (Fulcrum Therapeutics, Inc.), covering filings from Jul 22, 2019 onwards. 1 of those were filed in the last 90 days.
Are FULC insiders net buyers or net sellers?: Across the full Form 4 history for FULC, 21 transactions (15%) were open-market purchases and 69 (49%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does FULC insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is FULC in?: Fulcrum Therapeutics, Inc. (FULC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $725.67M.

Methodology & sources

Every FULC insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.